Available technologies

Novel inhibitor of neuropathic pain

Reference number: 5884

This novel neutralising antibody-based approach offers an innovative and valuable therapeutic strategy for patients with neuropathic pain.

Proposed use

Neuropathic pain is a chronic pain condition initiated or caused by a primary lesion or dysfunction of the nervous system. The prevalence of neuropathic pain is estimated to be 6-8% in the adult population and accounts for up to 25% of all individuals with chronic pain.

Problem addressed

A major reason for the failure to develop effective drug therapy for neuropathic pain has been the difficulty in identifying targets that were truly related to neuropathic pain. The novel approach developed by Dr Okuse and Prof. Rice, disrupting TLPQ-21/ gC1qR interaction by neutralising antibodies, may have promise as a drug target for controlling neuropathic pain.

Technology overview

The team identified gC1qR as the receptor of TLQP-21, a VGF-derived neuropeptide,  and found that their direct interaction induces an increase of intracellular calcium in rat macrophages which finally leads to mechanical hypersensitivity in rats. The team then used blocking antibodies against gC1qR which successfully inhibited the response of macrophages to TLPQ-21 and resulted in a delayed onset of nerve injury-associated mechanical hypersensitivity in vivo.

Benefits

  • Our approach focuses on activation of macrophages, previously not studied in the context of neuropathic pain
  • VGF has been shown to be upregulated in almost all neuropathic pain models, thus it is the key molecule in neuropathic pain development, unlike many other molecules involved in a specific type of neuropathic pain
  • This approach is effective on two points, blocking 1) infiltration of macrophages to sensory nerves and 2) activation of macrophages which leads to secretion of a specific cytokine and hypersensitisation of nociceptive sensory neurons
  • Antibodies are specific to targets and tend to show less side effects compared to small molecules

Intellectual property information

Patents: US9718879, EP2807191

Link to published paper

Chen, Y. C., Pristerá, A., Ayub, M., Swanwick, R. S., Karu, K., Hamada, Y., Rice A.C. & Okuse, K. (2013). Identification of a receptor for neuropeptide VGF and its role in neuropathic pain. Journal of Biological Chemistry, 288(48), 34638-34646.

Inventor information

Dr Kenji Okuse, Professor Andrew Rice, and team

Download datasheet

contact

Stuart Sims

Industry Partnerships and Commercialisation Executive, Natural Sciences

s.sims@imperial.ac.uk

Contact us about this technology

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London